Journal Home > Volume 1 , Issue 4
iLIVER 2022, 1(4): 225-234 https://doi.org/10.1016/j.iliver.2022.10.001
Review | Open Access | Issue | Published: 04 November 2022

Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review

Show Author's Information Jingxin Yana,b,c,  Manjun Dengc,d,  Shunyu Konga,b,  Ting Lie,f,  Zhenwu Leia,  Lushun Zhangg,h,  Yutong Zhuangi,  Xin Heb,  Huanwei Wangb,  Haining Fanc,d( ),  Yingxing Guoa( )
Department of Interventional Therapies, Affiliated Hospital of Qinghai University, Xining, China
Department of Postgraduate, Qinghai University, Xining, China
Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Qinghai University, Xining, China
Qinghai Province Key Laboratory of Hydatid Disease Research, Xining, China
Department of Orthopedics, Sichuan Provincial People's Hospital, Chengdu, China
Department of Postgraduate, Chengdu Medical College, Chengdu, China
Department of Pathology and Pathophysiology, Chengdu Medical College, Chengdu, China
Center of Sichuan for Elderly Care and Health, Chengdu Medical College, Chengdu, China
Department of Neurosurgery, The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, Guangdong, China
Keywords:
Hepatocellular carcinoma, Transarterial chemoembolization, Programmed death 1, Programmed cell death-ligand 1, Clinical evidence
Cite this article:
Yan J, Deng M, Kong S, et al. Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review. iLIVER, 2022, 1(4): 225-234. https://doi.org/10.1016/j.iliver.2022.10.001
Download citation
EndNote(RIS)
BibTeX

346

Views

4

Downloads

Citations

4

Crossref

N/A

WoS

N/A

Scopus

N/A

CSCD

Abstract Full text About this article

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. With the development of systemic therapies, several studies are currently underway, especially those related to the use of programmed death-1/programmed cell death-ligand 1 (PD-1/PD-L1) immunotherapy. Moreover, studies on transarterial chemoembolization (TACE) and PD-1/PD-L1 immunotherapy have demonstrated some interesting outcomes. This article reviewed the current clinical evidence on the combination of TACE and PD-1/PD-L1 immunotherapy. Overall, our review summarized that a favorable survival time could be achieved using this combination in most patients. However, complications such as hyperprogression should be taken seriously, and the underlying mechanisms need to be explored.


menu
Abstract
Full text
Outline
About this article

Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review

Show Author's information Jingxin Yana,b,c, Manjun Dengc,d, Shunyu Konga,b, Ting Lie,f, Zhenwu Leia, Lushun Zhangg,h, Yutong Zhuangi, Xin Heb, Huanwei Wangb, Haining Fanc,d( ), Yingxing Guoa( )
Department of Interventional Therapies, Affiliated Hospital of Qinghai University, Xining, China
Department of Postgraduate, Qinghai University, Xining, China
Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Qinghai University, Xining, China
Qinghai Province Key Laboratory of Hydatid Disease Research, Xining, China
Department of Orthopedics, Sichuan Provincial People's Hospital, Chengdu, China
Department of Postgraduate, Chengdu Medical College, Chengdu, China
Department of Pathology and Pathophysiology, Chengdu Medical College, Chengdu, China
Center of Sichuan for Elderly Care and Health, Chengdu Medical College, Chengdu, China
Department of Neurosurgery, The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, Guangdong, China

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. With the development of systemic therapies, several studies are currently underway, especially those related to the use of programmed death-1/programmed cell death-ligand 1 (PD-1/PD-L1) immunotherapy. Moreover, studies on transarterial chemoembolization (TACE) and PD-1/PD-L1 immunotherapy have demonstrated some interesting outcomes. This article reviewed the current clinical evidence on the combination of TACE and PD-1/PD-L1 immunotherapy. Overall, our review summarized that a favorable survival time could be achieved using this combination in most patients. However, complications such as hyperprogression should be taken seriously, and the underlying mechanisms need to be explored.

Keywords: Hepatocellular carcinoma, Transarterial chemoembolization, Programmed death 1, Programmed cell death-ligand 1, Clinical evidence

References(81)

[1]

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6): 394–424. https://doi.org/10.3322/caac.21492.
DOI Google Scholar
[2]

Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol 2020;72(2): 250–61. https://doi.org/10.1016/j.jhep.2019.08.025.
DOI Google Scholar
[3]

Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;14(2): 16018. https://doi.org/10.1038/nrdp.2016.18.
DOI Google Scholar
[4]

Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18(5): 293–313. https://doi.org/10.1038/s41575-020-00395-0.
DOI Google Scholar
[5]

Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expet Opin Invest Drugs 2022;31(4): 379–91. https://doi.org/10.1080/13543784.2022.2008355.
DOI Google Scholar
[6]

Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr 2020; 9(4): 452–63. https://doi.org/10.21037/hbsn-20-480.
DOI Google Scholar
[7]

Lee CK, Chan SL, Chon HJ. Could we predict the response of immune checkpoint inhibitor treatment in hepatocellular carcinoma? Cancers 2022;14(13): 3213. https://doi.org/10.3390/cancers14133213.
DOI Google Scholar
[8]

Blanc JF, Debaillon-Vesque A, Roth G, et al. Hepatocellular carcinoma: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clin Res Hepatol Gastroenterol 2021;45(2): 101590. https://doi.org/10.1016/j.clinre.2020.101590.
DOI Google Scholar
[9]

Piñero F, Tanno M, Aballay Soteras G, et al. Argentinean Association for the Study of Liver Diseases (A.A.E.E. H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19(5): 546–69. https://doi.org/10.1016/j.aohep.2020.06.003.
DOI Google Scholar
[10]

Chen LT, Martinelli E, Cheng AL, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol 2020;31(3): 334–51. https://doi.org/10.1016/j.annonc.2019.12.001.
DOI Google Scholar
[11]

Li X, Qiu M, Wang S, et al. A Phase I dose-escalation, pharmacokinetics and foodeffect study of oral donafenib in patients with advanced solid tumours. Cancer Chemother Pharmacol 2020;85(3): 593–604. https://doi.org/10.1007/s00280-020-04031-1.
DOI Google Scholar
[12]

Guan H, Wang C, Zhao Z, et al. Cost-effectiveness of donafenib as first-line treatment of unresectable hepatocellular carcinoma in China. Adv Ther 2022;39(7): 3334–46. https://doi.org/10.1007/s12325-022-02185-3.
DOI Google Scholar
[13]

Chapin WJ, Hwang WT, Karasic TB, et al. Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Med; 2022. https://doi.org/10.1002/cam4.4906. Epub ahead of print.
DOI Google Scholar
[14]

Verset G, Borbath I, Karwal M, et al. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase Ⅱ KEYNOTE-224 trial. Clin Cancer Res 2022;28(12): 2547–54. https://doi.org/10.1158/1078-0432.CCR-21-3807.
DOI Google Scholar
[15]

Wu CJ, Lee PC, Hung YW, et al. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. Cancer Immunol Immunother; 2022. https://doi.org/10.1007/s00262-022-03185-6. Online ahead of print.
DOI Google Scholar
[16]

Toshida K, Itoh S, Tomiyama T, et al. Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients. JGH Open 2022;6(7): 477–86. https://doi.org/10.1002/jgh3.12777.
DOI Google Scholar
[17]

Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 2022. https://doi.org/10.1038/s41591-022-01868-2. Online ahead of print.
DOI Google Scholar
[18]

Hatanaka T, Kakizaki S, Hiraoka A, et al. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatol Int 2022. https://doi.org/10.1007/s12072-022-10358-z. Online ahead of print.
DOI Google Scholar
[19]

Zhang T, Merle P, Wang H, et al. Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr 2021;10: 180–92. https://doi.org/10.21037/hbsn-2021-7.
DOI Google Scholar
[20]

Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18: 525–43. https://doi.org/10.1038/s41575-021-00438-0.
DOI Google Scholar
[21]

Ebert PJR, Cheung J, Yang Y, et al. MAP kinase inhibition promotes T cell and antitumor activity in combination with PD-L1 checkpoint blockade. Immunity 2016; 44(3): 609–21. 15.
DOI Google Scholar
[22]

Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 2015;21(7): 1639–51.
DOI Google Scholar
[23]

El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492–502. https://doi.org/10.1016/S0140-6736(17)31046-2.
DOI Google Scholar
[24]

Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a nonrandomised, open-label phase 2 trial. Lancet Oncol 2018;19:940–52. https://doi.org/10.1016/S1470-2045(18)30351-6.
DOI Google Scholar
[25]

Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumabplus bevacizumab vs.sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4): 862–73. https://doi.org/10.1016/j.jhep.2021.11.030.
DOI Google Scholar
[26]

Cheon J, Yoo C, Hong JY, et al. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver Int 2022;42(3): 674–81. https://doi.org/10.1111/liv.15102.
DOI Google Scholar
[27]

Ivanics T, Salinas-Miranda E, Abreu P, et al. A pre-TACE radiomics model to predict HCC progression and recurrence in liver transplantation: a pilot study on a novel biomarker. Transplantation 2021;105(11): 2435–44. https://doi.org/10.1097/TP.0000000000003605.
DOI Google Scholar
[28]

Lu J, Zhang XP, Zhong BY, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol 2019;4(9): 721–30. https://doi.org/10.1016/S2468-1253(19)30178-5.
DOI Google Scholar
[29]

Cheng S, Chen M, Cai J. National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor Thrombus. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget 2017;8(5): 8867–76. https://doi.org/10.18632/oncotarget.12817.
DOI Google Scholar
[30]

Zhang S, Zhao Y, He L, et al. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2022;46(4): 101851. https://doi.org/10.1016/j.clinre.2021.101851.
DOI Google Scholar
[31]

Zhang M, Lai W, Zhang J, et al. Efficacy investigation of TACE combined with lenvatinib and sintilimab in intermediate-stage hepatocellular carcinoma. Dis Markers 2022;2022:6957580. https://doi.org/10.1155/2022/6957580.
DOI Google Scholar
[32]

Zhang JX, Chen YX, Zhou CG, et al. Efficacy and safety of the combination of transarterial chemoembolization with camrelizumab plus apatinib for advanced hepatocellular carcinoma: a retrospective study of 38 patients from a single center. Chin J Gastroenterol Hepatol 2022;2022:7982118. https://doi.org/10.1155/2022/7982118.
DOI Google Scholar
[33]

Zhang JX, Chen P, Liu S, et al. Safety and efficacy of transarterial chemoembolization and immune checkpoint inhibition with camrelizumab for treatment of unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 2022; 9:265–72. https://doi.org/10.2147/JHC.S358658.
DOI Google Scholar
[34]

Yang F, Xu GL, Huang JT, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: efficacy and systemic immune response. Front Immunol 2022;13:847601. https://doi.org/10.3389/fimmu.2022.847601.
DOI Google Scholar
[35]

Xiang YJ, Wang K, Yu HM, et al. Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma. Hepatol Res; 2022. https://doi.org/10.1111/hepr.13773. Epub ahead of print.
DOI Google Scholar
[36]

Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma 2021;8: 1233–40. https://doi.org/10.2147/JHC.S332420.
DOI Google Scholar
[37]

Teng Y, Ding X, Li W, et al. A retrospective study on therapeutic efficacy of transarterial chemoembolization combined with immune checkpoint inhibitors plus lenvatinib in patients with unresectable hepatocellular carcinoma. Technol Cancer Res Treat 2022;21:15330338221075174. https://doi.org/10.1177/15330338221075174.
DOI Google Scholar
[38]

Ren Y, Guo Y, Chen L, et al. Efficacy of drug-eluting beads transarterial chemoembolization plus camrelizumab compared with conventional transarterial chemoembolization plus camrelizumab for unresectable hepatocellular carcinoma. Cancer Control 2022;29:10732748221076806. https://doi.org/10.1177/10732748221076806.
DOI Google Scholar
[39]

Qu S, Zhang X, Wu Y, et al. Efficacy and safety of TACE combined with lenvatinib plus PD-1 inhibitors compared with TACE alone for unresectable hepatocellular carcinoma patients: a prospective cohort study. Front Oncol 2022;12:874473. https://doi.org/10.3389/fonc.2022.874473.
DOI Google Scholar
[40]

Qin J, Huang Y, Zhou H, et al. Efficacy of sorafenib combined with immunotherapy following transarterial chemoembolization for advanced hepatocellular carcinoma: a propensity score analysis. Front Oncol 2022;12:807102. https://doi.org/10.3389/fonc.2022.807102.
DOI Google Scholar
[41]

Marinelli B, Kim E, D'Alessio A, et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer 2022;10(6): e004205. https://doi.org/10.1136/jitc-2021-004205.
DOI Google Scholar
[42]

Liu J, Li Z, Zhang W, et al. Comprehensive treatment of trans-arterial chemoembolization plus lenvatinib followed by camrelizumab for advanced hepatocellular carcinoma patients. Front Pharmacol 2021;12:709060. https://doi.org/10.3389/fphar.2021.709060.
DOI Google Scholar
[43]

Li X, Fu Z, Chen X, et al. Efficacy and safety of lenvatinib combined with PD-1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients in China real-world. Front Oncol 2022;12:950266. https://doi.org/10.3389/fonc.2022.950266.
DOI Google Scholar
[44]

Ju S, Zhou C, Yang C, et al. Apatinib plus camrelizumab with/without chemoembolization for hepatocellular carcinoma: a real-world experience of a single center. Front Oncol 2022;11:835889. https://doi.org/10.3389/fonc.2021.835889.
DOI Google Scholar
[45]

Ju S, Zhou C, Hu J, et al. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination. BMC Cancer 2022;22(1): 335. https://doi.org/10.1186/s12885-022-09451-1.
DOI Google Scholar
[46]

Huang Y, Zhang Z, Liao W, et al. Combination of sorafenib, camrelizumab, transcatheter arterial chemoembolization, and stereotactic body radiation therapy as a novel downstaging strategy in advanced hepatocellular carcinoma with portal vein tumor thrombus: a case series study. Front Oncol 2021;11:650394. https://doi.org/10.3389/fonc.2021.650394.
DOI Google Scholar
[47]

Guo Y, Ren Y, Chen L, et al. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer 2022;22(1): 270. https://doi.org/10.1186/s12885-022-09325-6.
DOI Google Scholar
[48]

Chen S, Wu Z, Shi F, et al. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. J Cancer Res Clin Oncol 2022;148(8): 2115–25. https://doi.org/10.1007/s00432-021-03767-4.20.
DOI Google Scholar
[49]

Cao F, Yang Y, Si T, et al. The efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a multicenter retrospective study. Front Oncol 2021;11:783480. https://doi.org/10.3389/fonc.2021.783480.21.
DOI Google Scholar
[50]

Cai M, Huang W, Huang J, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol 2022;13:848387. https://doi.org/10.3389/fimmu.2022.848387.
DOI Google Scholar
[51]

Zhu Y, Sun P, Wang K, et al. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. Cancer Cell Int 2021;21(1): 503. https://doi.org/10.1186/s12935-021-02200-7.
DOI Google Scholar
[52]

Xie D, Sun Q, Wang X, et al. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. Ann Transl Med 2021;9(8): 652. https://doi.org/10.21037/atm-20-7037.
DOI Google Scholar
[53]

Kudo M. Immuno-oncology in hepatocellular carcinoma. Oncology 2017;93(Suppl 1): 147–59. http://doi.org/10.1159/000481245.
DOI Google Scholar
[54]

Lin YY, Tan CT, Chen CW, et al. Immunomodulatory effects of current targeted therapies on hepatocellular carcinoma: implication for the future of immunotherapy. Semin Liver Dis 2018;38(4): 379–88. http://doi.org/10.1055/s-0038-1673621.
DOI Google Scholar
[55]

Baba Y, Nomoto D, Okadome K, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci 2020;111(9): 3123–41. http://doi.org/10.1111/cas.14541.
DOI Google Scholar
[56]

Vogelsang M, Wang Y, Veber N, et al. The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. PLoS One 2012;7(5): e36962. http://doi.org/10.1371/journal.pone.0036962.
DOI Google Scholar
[57]

Zhu XD, Tang ZY, Sun HC. Targeting angiogenesis for liver cancer: past, present, and future. Genes Dis 2020;7(3): 328–35. http://doi.org/10.1016/j.gendis.2020.03.010.
DOI Google Scholar
[58]

Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020;21(4): 571–80. https://doi.org/10.1016/S1470-2045(20)30011-5.
DOI Google Scholar
[59]

Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a singlearm, open label, phase Ⅱ clinical trial. J Immunother Cancer 2022;10(4): e004656. https://doi.org/10.1136/jitc-2022-004656.
DOI Google Scholar
[60]

Gou M, Qian N, Zhang Y, et al. Fruquintinib in combination with PD-1 inhibitors in patients with refractory non-MSI-H/pMMR metastatic colorectal cancer: a realworld study in China. Front Oncol 2022;12:851756. https://doi.org/10.3389/fonc.2022.851756.
DOI Google Scholar
[61]

Cao H, Wei W, Lu Y. Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: treatment response, survival pattern, and safety. J Clin Pharm Ther 2022. https://doi.org/10.1111/jcpt.13732. Online ahead of print.
DOI Google Scholar
[62]

Wang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs 2019;11(8): 1443–51. https://doi.org/10.1080/19420862.2019.1654303.
DOI Google Scholar
[63]

Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014;26:605–22. https://doi.org/10.1016/j.ccell.2014.10.006.
DOI Google Scholar
[64]

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial. Lancet 2018;391(10126): 1163–73. https://doi.org/10.1016/s0140-6736(18)30207-1.
DOI Google Scholar
[65]

Cremolini C, Loupakis F, Antoniotti C, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase Ⅲ TRIBE trial by the gruppo oncologico del nord ovest. Ann Oncol 2015;26(6): 1188–94. https://doi.org/10.1093/annonc/mdv112.
DOI Google Scholar
[66]

Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 2019;10:ED000142. https://doi.org/10.1002/14651858.ED000142.
DOI Google Scholar
[67]

Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017; 23:1920–8. https://doi.org/10.1158/1078-0432.CCR-16-1741.
DOI Google Scholar
[68]

Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018;4(11): 1543–52. https://doi.org/10.1001/jamaoncol.2018.3676.
DOI Google Scholar
[69]

Sasaki A, Nakamura Y, Mishima S, et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer 2019;22(4): 793–802. https://doi.org/10.1007/s10120-018-00922-8.
DOI Google Scholar
[70]

Saâda-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during antiPD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28(7): 1605–11. https://doi.org/10.1093/annonc/mdx178.
DOI Google Scholar
[71]

Viehl CT, Moore TT, Liyanage UK, et al. Depletion of CD4þCD25þ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 2006;13(9): 1252–8. https://doi.org/10.1245/s10434-006-9015-y.
DOI Google Scholar
[72]

Lowther DE, Goods BA, Lucca LE, et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 2016;1(5): e85935. https://doi.org/10.1172/jci.insight.85935.
DOI Google Scholar
[73]

Ringelhan M, Pfister D, O'Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol 2018;19:222–32. https://doi.org/10.1038/s41590-018-0044-z.
DOI Google Scholar
[74]

Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454(7203): 436–44. https://doi.org/10.1038/nature07205.
DOI Google Scholar
[75]

Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017;23(15): 4242–50. https://doi.org/10.1158/1078-0432.CCR-16-3133.
DOI Google Scholar
[76]

Wartewig T, Kurgyis Z, Keppler S, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 2017;552(7683): 121–5. https://doi.org/10.1038/nature24649.
DOI Google Scholar
[77]

Ludin A, Zon LI. Cancer immunotherapy: the dark side of PD-1 receptor inhibition. Nature 2017;552(7683): 41–2. https://doi.org/10.1038/nature24759.
DOI Google Scholar
[78]

Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/Ⅱ study. J Clin Oncol 2021;39(27): 2991–3001. http://doi.org/10.1200/JCO.20.03555.
DOI Google Scholar
[79]

Rao Q, Li M, Xu W, et al. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2020; 14(5): 765–75. https://doi.org/10.1007/s12072-020-10064-8.
DOI Google Scholar
[80]

Liu Z, Liu X, Liang J, et al. Immunotherapy for hepatocellular carcinoma: current status and future prospects. Front Immunol 2021;12:765101. https://doi.org/10.3389/fimmu.2021.765101.
DOI Google Scholar
[81]

Pfister D, Núñez NG, Pinyol R, et al. NASH limits antitumour surveillance in immunotherapy-treated HCC. Nature 2021;592(7854): 450–6. https://doi.org/10.1038/s41586-021-03362-0.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 05 September 2022
Revised: 24 October 2022
Accepted: 25 October 2022
Published: 04 November 2022
Issue date: December 2022

Copyright

© 2022 The Author(s). Published by Elsevier Ltd on behalf of Tsinghua University Press.

Acknowledgements

The authors would like to thank Miss Xianmei Wang for her assistance with this work.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return